An observational study in Endometrial Cancer, sponsored by AstraZeneca. Recruiting at 49 sites in Germany. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by AstraZeneca · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.
Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is one of 7 that started in 2025, is one of 5 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 12th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in United States
Ages 18–130
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+ · Women only
AstraZeneca · Sites in Russia
Ages 18+ · Women only
AstraZeneca · Sites in United States, Australia, Austria and 20 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 4
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Median enrollment 457 across the 12 interventional studies, 140 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
6 of the studies in Endometrial Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
| NCT07041606AstraZenecaAn Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation | 2027-06-30 |
| NCT06218914AstraZenecaPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | 2027-08-30 |
| NCT05123482AstraZenecaA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | 2027-09-29 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies in Endometrial Neoplasms by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.
This is a multi-center, prospective, non-interventional study (NIS) to collect real-world clinical and PRO data in patients with primary advanced (FIGO stage III or IV) or recurrent EC receiving 1L CPD followed by maintenance therapy with durvalumab (DNA mismatch repair deficient; dMMR cohort) or durvalumab and olaparib (DNA mismatch repair proficient, pMMR cohort) in accordance with the applicable SmPC within routine clinical practice. Following surgery and/or radiation (if applicable) the decision to initiate 1L CPD followed by durvalumab or durvalumab and olaparib is made in a shared decision between the patient and the treating physician as part of routine care outside of and independent of this study.
The aim of the NIS is to describe the outcomes including effectiveness and safety of patients with primary advanced and recurrent EC treated with the two approved 1L regimens of CPD followed by durvalumab maintenance and CPD followed by durvalumab and olaparib maintenance, as well as patient-reported outcomes after chemotherapy-phase (CPD) in Germany. The study also aims to better understand characteristics of patients with primary advanced or recurrent EC that benefit from maintenance therapy with durvalumab or durvalumab and olaparib.
150 patients with documented primary advanced (FIGO stage III or IV) or recurrent EC of epithelial histology (excluding sarcomas) who are eligible for first-line therapy with CPD followed by durvalumab or durvalumab and olaparib in line with the applicable SmPC within routine clinical practice will be recruited in Germany. The study allows recruitment of patients that already started and may have received up to 2 cycles of CPD. Inclusion of patients having started CPD will be capped to 25% for each cohort of the study population. Testing results for MMR status of the patients' tumor must be available. Patients must be willing and able to report PROs. Eligible patients will be included into the study after and independently of the treating physician's treatment and diagnostic decisions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary advanced or recurrent endometrial cancer receiving 1L regimens of CPD with prior tested dMMR status. Following the SmPC patients of this cohort will receive durvalumab in the maintenance phase if they achieved and maintained disease control, i.e., complete response (CR), partial response (PR), or stable disease (SD) with CPD during the chemotherapy phase.
Patients with primary advanced or recurrent endometrial cancer receiving 1L regimens of CPD with prior tested pMMR status. Following the SmPC patients of this cohort will receive durvalumab and olaparib in the maintenance phase if they achieved and maintained disease control i.e., CR, PR, or SD with CPD during the chemotherapy phase.
This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Real-world Time To Next Treatment (rwTTNT)
rwTTNT is defined as time from start of 1L CPD until first dose of next systemic therapy or start of any other next anticancer therapy or death from any cause. 1L maintenance therapy with durvalumab or durvalumab+olaparib is not considered as next systemic therapy. The measure of interest is the landmark at 12 months of time to first next therapy or death (rwTTNT).
Time frame: At 12 months
Real-world Progression-free Survival (rwPFS)
rwPFS is defined as time from start of 1L CPD until progression or death from any cause. The measure of interest is the landmark at 12 months of progression-free survival (rwPFS).
Time frame: At 12 months
Time to deterioration in health-related quality of life (HRQoL) based on EORTC QLQ-C30 questionnaire compared to baseline over time
The European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30), is a validated 30-item self-administered core questionnaire designed to assess HRQoL, functioning, and symptoms in all cancer patients or survivors. Time to deterioration is defined as time from baseline (≤ 14 days before first application of maintenance therapy) to date of first clinically meaningful deterioration i.e. a decrease by ≥10 points for the functional scales and an increase by ≥ 10 points for the symptom scales or death in: * Physical functioning score * Role functioning score
Time frame: Baseline to first clinically meaningful deterioration, up to 46 months
Time to deterioration in HRQoL based on EORTC QLQ-EN24 questionnaire compared to baseline over time
The Endometrial Cancer Module EORTC QLQ-EN24, is a validated disease-specific extension to the EORTC QLQ-C30 designed to assess disease and treatment specific aspects of the QoLof patients with all stages of EC. The module consists of 24 questions grouped into 13 scales. Time to deterioration is defined as time from baseline (≤ 14 days before first application of maintenance therapy) to date of first clinically meaningful deterioration i.e. a decrease by ≥10 points for the functional scales and an increase by ≥ 10 points for the symptom scales or death in: * Back/pelvic pain * Gastrointestinal (GI) symptoms * Urological symptoms
Time frame: Baseline to first clinically meaningful deterioration, up to 46 months
Duration of maintenance therapy
Time from first dose of maintenance therapy with durvalumab or durvalumab+olaparib to the last dose/cyle of durvalumab or olaparib, whatever is last, including number and duration of treatment interruptions.
Time frame: From first dose of maintenance therapy up to 46 months
Duration of 1L CPD
Duration of therapy with durvalumab with carboplatin and/or paclitaxel
Time frame: Assessed up to 46 months
Time between end of CPD until start of maintenance therapy
Time to start maintenance therapy defined as date of last cycle of chemotherapy until date of first dose of maintenance therapy
Time frame: Assessed up to 46 months
Usage of treatment therapy
Dose, dose change, treatment interruption, number of cycles, cumulative dose of durvalumab.
Time frame: Assessed up to 46 months
Safety: Collection of Adverse Events (AE)
Safety evaluated based on type of Adverse Event (AE), intensity, causal relationship to treatment, duration, handling, outcome, and seriousness.
Time frame: During routine visits up to 46 months
Change in timed up and go test (TUG)
The Timed up and go test (TUG) is a reliable and validated measure of functional mobility that can be used to assess frailty and functional impairment and to predict the risk of postoperative complications. The TUG records the time it takes a patient to get up from an armchair, walk 3 meters, turn around, walk back, and sit down again. Aids such as walking aids are permitted but help from other people is not. TUG should be assesd at every routine visit.
Time frame: Baseline up to 46 months
Change in EORTC QLQ-C30
Changes of patient-reported outcomes (PROs) based on the European Organisation for Research and Treatment of Cancer Quality of Life - Core Questionnaire 30 (EORTC QLQ-C30) questionnaire from baseline (defined as ≤ 14 days before first application of maintenance therapy) over time in: * Physical functioning score of EORTC QLQC30 * Role functioning score of the EORTC QLQ-C30 * Global health status/quality of life (QoL) score of the EORTC QLQ-C30 * All other functioning and symptom subscale scores of the EORTC QLQ-C30.
Time frame: Baseline up to 46 months
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Mar 2029, 46 months after the start.
Of 150 observational studies under Endometrial Neoplasms, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 206. This study's planned 46 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.